Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 26

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Study on Colchicine for Patients with Coronary Artery Disease After Percutaneous Coronary Intervention

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Az St-Jan Brugge-Oostende A.V.

Study on Predicting Blood Pressure Response in Hypertension Patients Using Amlodipine, Olmesartan Medoxomil, Hydrochlorothiazide, and Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amlodipine
  • Sponsor:Stichting Radboud University Medical Center

Study on the Effectiveness and Safety of Treprostinil and Drug Combination for Patients with Pulmonary Arterial Hypertension (Group I)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Skin ulcer

Recruiting

Study on Acetic Acid for Healing Skin Ulcers in Patients with Biofilm

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetic Acid, Glacial
  • Sponsor:Consorci Sanitari De L'Alt Penedes I Garraf

Dementia+5

Recruiting

Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetaben (18F)
  • Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Study on the Effectiveness of Somatostatin Eye Drops for Patients with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Somatostatin
  • Sponsor:Bcn Peptides S.A.

Study on Monitoring vs. Rivaroxaban for Patients with Low-Risk Isolated Subsegmental Pulmonary Embolism

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Insel Gruppe AG

Study on the Use of Allogenic Adipose-Tissue-Derived Mesenchymal Stem Cells for Healing Chronic Digital Ulcers in Systemic Sclerosis Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Study on the Effect of Influenza Vaccine on Heart Inflammation After Heart Attack for Patients with Myocardial Infarction

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Region Oerebro Laen

Study on Sotatercept for Children with Pulmonary Arterial Hypertension Receiving Standard Care

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Study on Protamine Sulfate to Reduce Neurological Events After Aortic Valve Implantation in Patients with Aortic Stenosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Protamine Sulfate
  • Sponsor:Assistance Publique Hopitaux De Paris

Dermatomyositis+2

Recruiting

Study on Filgotinib for Patients with Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:Universitair Medisch Centrum Utrecht

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.